After customs duty cuts on 17 cancer drugs, India’s price regulator ordered MRPs revised to pass on benefits, but activists say tax relief alone won’t make costly patented therapies affordable.

Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic lymphocytic leukemia (CLL) has undergone a seismic shift, moving from the ...

The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...

The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...

Budget 2026 duty cuts may lower prices of 17 drugs, but experts say cancer treatment choices will still depend on clinical evidence, not cost alone, despite modest savings.

An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...

FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology ...

NPPA asks cos to revise prices of 17 drugs following BCD exemption: Gireesh Babu, New Delhi Thursday, February 12, 2026, 08:00 Hrs [IST] The National Pharmaceutical Pricing Author ...

In the Union Budget, custom duty on 17 cancer therapies have been slashed. But, high-cost therapies are still out of reach ...

In the Union Budget, custom duty on 17 cancer therapies have been slashed. But, high-cost therapies are still out of reach for many.

While exemptions on key imported cancer therapies promise reduced treatment costs for patients, oncologists say preventing ...

The Union Budget 2026-27 signals one of the most comprehensive expansions of India's healthcare vision in recent years, ...